Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology plc - Ordinary Shares (MURA)
Company Research
Source: GlobeNewswire
WALTHAM, Mass. and DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on April 1, the Company granted to four newly hired employees (i) non-statutory stock options to purchase an aggregate of 25,675 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 13,825 ordinary shares of the Company, pursuant to the Company’s 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $4.85 per share, which is equal to the closing price per share of the Comp
Show less
Read more
Impact Snapshot
Event Time:
MURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MURA alerts
High impacting Mural Oncology plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MURA
News
- Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual MeetingGlobeNewswire
- Mural Oncology plc (NASDAQ: MURA) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $13.00 price target on the stock.MarketBeat
MURA
Sec Filings
- 5/14/24 - Form 10-Q
- 5/14/24 - Form 8-K
- 5/8/24 - Form SC
- MURA's page on the SEC website